You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxaprozin
Accession NumberDB00991  (APRD00030)
TypeSmall Molecule
GroupsApproved
DescriptionOxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Structure
Thumb
Synonyms
Danoprox
Daypro
Dayrun
Deflam
Duraprox
Oxaprozina
Oxaprozine
Oxaprozinum
Walix
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DayproTablet, film coated600 mg/1OralPd Rx Pharmaceuticals, Inc.1992-10-29Not applicableUs
DayproTablet, film coated600 mg/1OralG.D. Searle LLC Division of Pfizer Inc1992-10-29Not applicableUs
DayproTablet600 mgOralPfizer Canada Inc1997-01-072012-09-20Canada
OxaprozinTablet, film coated600 mg/1OralGreenstone LLC2013-03-28Not applicableUs
Rhoxal-oxaprozinTablet600 mgOralRhoxalpharma Inc2001-06-112009-11-24Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxaprozinTablet600 mgOralApotex Inc2001-05-29Not applicableCanada
OxaprozinTablet, film coated600 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-08Not applicableUs
OxaprozinTablet, film coated600 mg/1OralPreferred Pharmaceuticals, Inc2012-02-14Not applicableUs
OxaprozinTablet600 mg/1OralSTAT Rx USA LLC2001-01-31Not applicableUs
OxaprozinTablet, film coated600 mg/1OralTeva Pharmaceuticals USA Inc2003-05-12Not applicableUs
OxaprozinTablet600 mg/1OralDispensing Solutions, Inc.2001-01-31Not applicableUs
OxaprozinTablet, film coated600 mg/1OralUnit Dose Services2010-09-08Not applicableUs
OxaprozinTablet, film coated600 mg/1OralA S Medication Solutions2001-01-31Not applicableUs
OxaprozinTablet600 mg/1OralCaraco Pharmaceutical Laboratories, Ltd.2002-01-03Not applicableUs
OxaprozinTablet, film coated600 mg/1OralRebel Distributors Corp2010-09-08Not applicableUs
OxaprozinTablet600 mg/1OralEon Labs, Inc.2001-01-31Not applicableUs
OxaprozinTablet600 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
OxaprozinTablet, film coated600 mg/1OralA S Medication Solutions2001-01-31Not applicableUs
OxaprozinTablet, film coated600 mg/1OralH.J. Harkins Company, Inc.2001-01-31Not applicableUs
OxaprozinTablet, film coated600 mg/1OralApotex Corp.2004-09-03Not applicableUs
OxaprozinTablet600 mg/1OralAv Kare, Inc.2014-03-06Not applicableUs
OxaprozinTablet, film coated600 mg/1OralDr. Reddy's Laboratories Limited2001-01-31Not applicableUs
OxaprozinTablet600 mg/1OralCarilion Materials Management2001-01-31Not applicableUs
OxaprozinTablet600 mg/1OralPhysicians Total Care, Inc.2001-09-04Not applicableUs
OxaprozinTablet600 mg/1OralDIRECT RX2014-01-01Not applicableUs
OxaprozinTablet, film coated600 mg/1Oralbryant ranch prepack2010-09-08Not applicableUs
OxaprozinTablet, film coated600 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-05-26Not applicableUs
OxaprozinTablet, film coated600 mg/1OralClinical Solutions Wholesale2001-01-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlvoNot Available
Daypro AltaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxaprozin potassium
ThumbNot applicableDBSALT001452
Categories
UNIIMHJ80W9LRB
CAS number21256-18-8
WeightAverage: 293.3166
Monoisotopic: 293.105193351
Chemical FormulaC18H15NO3
InChI KeyOFPXSFXSNFPTHF-UHFFFAOYSA-N
InChI
InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
IUPAC Name
3-(diphenyl-1,3-oxazol-2-yl)propanoic acid
SMILES
OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
Pharmacology
IndicationUsed to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
Structured Indications
PharmacodynamicsOxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
Mechanism of actionAnti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Related Articles
AbsorptionOxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.
Volume of distribution
  • 11 to 17 L/70 kg
Protein binding>99.5% bound to albumin
Metabolism

Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.

Route of eliminationOxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite. Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.
Half life54.9 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 1210 mg/kg; Oral, rabbit: LD50 = 172 mg/kg; Oral, rat: LD50 = 4470 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxaprozin Action PathwayDrug actionSMP00113
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with 5-androstenedione.Experimental, Illicit
AbciximabOxaprozin may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Oxaprozin can be decreased when combined with Abiraterone.Approved
AcebutololOxaprozin may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aceclofenac.Approved
AcenocoumarolOxaprozin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oxaprozin.Approved, Vet Approved
AclarubicinOxaprozin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oxaprozin.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.Approved
AliskirenOxaprozin may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololOxaprozin may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxaprozin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Amcinonide.Approved
AmikacinOxaprozin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideOxaprozin may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Oxaprozin can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinOxaprozin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodOxaprozin may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Anisodamine.Investigational
annamycinOxaprozin may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Antipyrine.Approved
Antithrombin III humanOxaprozin may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Oxaprozin may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanOxaprozin may increase the anticoagulant activities of Apixaban.Approved
ApramycinOxaprozin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Oxaprozin can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinOxaprozin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinOxaprozin may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanOxaprozin may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololOxaprozin may decrease the antihypertensive activities of Arotinolol.Approved
AtenololOxaprozin may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxaprozin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.Approved
BalsalazideOxaprozin may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminOxaprozin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololOxaprozin may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxaprozin.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxaprozin.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Oxaprozin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Betamethasone.Approved, Vet Approved
BetaxololOxaprozin may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Betulinic Acid.Investigational
BevantololOxaprozin may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxaprozin.Approved, Investigational
BisoprololOxaprozin may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOxaprozin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololOxaprozin may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxaprozin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Bucillamine.Investigational
BucindololOxaprozin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Budesonide.Approved
BufuralolOxaprozin may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideOxaprozin may decrease the diuretic activities of Bumetanide.Approved
BupranololOxaprozin may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxaprozin.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxaprozin.Experimental
CapecitabineThe metabolism of Oxaprozin can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Oxaprozin.Approved
CarbamazepineThe metabolism of Oxaprozin can be increased when combined with Carbamazepine.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxaprozin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxaprozin.Approved, Vet Approved, Withdrawn
CarteololOxaprozin may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolOxaprozin may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Celecoxib.Approved, Investigational
CeliprololOxaprozin may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Oxaprozin can be increased when it is combined with Ceritinib.Approved
CertoparinOxaprozin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxaprozin.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxaprozin.Approved
CholecalciferolThe metabolism of Oxaprozin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxaprozin.Approved
CinoxacinOxaprozin may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinOxaprozin may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidOxaprozin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Oxaprozin.Vet Approved
ClotrimazoleThe metabolism of Oxaprozin can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Curcumin.Investigational
CyclosporineOxaprozin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Oxaprozin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with D-Limonene.Investigational
Dabigatran etexilateOxaprozin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Oxaprozin can be decreased when it is combined with Dabrafenib.Approved
DalteparinOxaprozin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOxaprozin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinOxaprozin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Oxaprozin can be decreased when combined with Delavirdine.Approved
DesirudinOxaprozin may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxaprozin.Approved
DextranOxaprozin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Oxaprozin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Oxaprozin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Oxaprozin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxaprozin.Approved, Vet Approved
DicoumarolOxaprozin may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxaprozin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Oxaprozin.Approved
DihydrostreptomycinOxaprozin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Oxaprozin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxaprozin.Approved
DoxorubicinOxaprozin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneOxaprozin may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Oxaprozin is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ebselen.Investigational
Edetic AcidOxaprozin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOxaprozin may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Oxaprozin can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxaprozin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxaprozin.Approved
EnoxacinOxaprozin may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinOxaprozin may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Epirizole.Approved
EpirubicinOxaprozin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneOxaprozin may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxaprozin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxaprozin.Approved
EquileninThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Equilin.Approved
EsmololOxaprozin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone sulfate.Approved
Etacrynic acidOxaprozin may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Oxaprozin.Approved, Investigational
Ethyl biscoumacetateOxaprozin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Oxaprozin can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Oxaprozin is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxaprozin.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Oxaprozin.Vet Approved
FleroxacinOxaprozin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oxaprozin.Approved, Withdrawn
FloxuridineThe metabolism of Oxaprozin can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with fluasterone.Investigational
FluconazoleThe metabolism of Oxaprozin can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fludrocortisone.Approved
FluindioneOxaprozin may increase the anticoagulant activities of Fluindione.Investigational
FlumequineOxaprozin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluorometholone.Approved
FluorouracilThe metabolism of Oxaprozin can be decreased when combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Oxaprozin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxaprozin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Oxaprozin can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Oxaprozin can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxaprozin.Approved, Nutraceutical, Vet Approved
FondaparinuxOxaprozin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumOxaprozin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxaprozin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxaprozin.Approved
FosphenytoinThe metabolism of Oxaprozin can be increased when combined with Fosphenytoin.Approved
FramycetinOxaprozin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideOxaprozin may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateOxaprozin may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinOxaprozin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOxaprozin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxaprozin.Approved, Withdrawn
GemfibrozilThe metabolism of Oxaprozin can be decreased when combined with Gemfibrozil.Approved
GemifloxacinOxaprozin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOxaprozin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinOxaprozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOxaprozin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinOxaprozin may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Oxaprozin is combined with HE3286.Investigational
HeparinOxaprozin may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Higenamine.Investigational
HirulogOxaprozin may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Oxaprozin is combined with HMPL-004.Investigational
HydralazineOxaprozin may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxaprozin.Approved
Hygromycin BOxaprozin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Icatibant.Approved
IdarubicinOxaprozin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxOxaprozin may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxaprozin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Oxaprozin.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.Approved
IndenololOxaprozin may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Oxaprozin can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Indoprofen.Withdrawn
INNO-206Oxaprozin may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Oxaprozin can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Istaroxime.Investigational
KanamycinOxaprozin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Oxaprozin can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxaprozin.Approved
LabetalolOxaprozin may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxaprozin.Approved, Investigational
LeflunomideThe metabolism of Oxaprozin can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinOxaprozin may increase the anticoagulant activities of Lepirudin.Approved
LevobunololOxaprozin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinOxaprozin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Oxaprozin.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Oxaprozin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Oxaprozin.Approved
LomefloxacinOxaprozin may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.Approved
LosartanThe metabolism of Oxaprozin can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Oxaprozin can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxaprozin.Approved, Investigational
LumacaftorThe serum concentration of Oxaprozin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Oxaprozin.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxaprozin.Approved
ME-609The risk or severity of adverse effects can be increased when Oxaprozin is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxaprozin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.Approved, Vet Approved
MesalazineOxaprozin may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Methylprednisolone.Approved, Vet Approved
MetipranololOxaprozin may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.Approved
MetoprololOxaprozin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideOxaprozin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MifepristoneThe serum concentration of Oxaprozin can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxaprozin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxaprozin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxaprozin.Approved
MoxifloxacinOxaprozin may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxaprozin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nabumetone.Approved
NadololOxaprozin may decrease the antihypertensive activities of Nadolol.Approved
NadroparinOxaprozin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatOxaprozin may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Oxaprozin.Approved
Nalidixic AcidOxaprozin may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxaprozin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Oxaprozin is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Oxaprozin is combined with NCX 4016.Investigational
NeamineOxaprozin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinOxaprozin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinOxaprozin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nepafenac.Approved
NetilmicinOxaprozin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe metabolism of Oxaprozin can be decreased when combined with Nicardipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nitroaspirin.Investigational
NorfloxacinOxaprozin may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinOxaprozin may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxaprozin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.Approved
OlsalazineOxaprozin may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Oxaprozin.Investigational
OmeprazoleThe metabolism of Oxaprozin can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Orgotein.Vet Approved
OtamixabanOxaprozin may increase the anticoagulant activities of Otamixaban.Investigational
OxprenololOxaprozin may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Parecoxib.Approved
ParomomycinOxaprozin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinOxaprozin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOxaprozin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOxaprozin may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateOxaprozin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxaprozin.Approved
PhenindioneOxaprozin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Oxaprozin can be increased when combined with Phenobarbital.Approved
PhenprocoumonOxaprozin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxaprozin.Approved, Vet Approved
PhenytoinThe metabolism of Oxaprozin can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaprozin.Approved, Investigational
PindololOxaprozin may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinOxaprozin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideOxaprozin may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.Approved, Investigational
PlicamycinOxaprozin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxaprozin.Approved
PractololOxaprozin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Oxaprozin.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pregnenolone.Experimental
PrimidoneThe metabolism of Oxaprozin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Oxaprozin can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Propacetamol.Approved
PropranololOxaprozin may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Oxaprozin.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Oxaprozin.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Oxaprozin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Oxaprozin.Vet Approved
Protein COxaprozin may increase the anticoagulant activities of Protein C.Approved
Protein S humanOxaprozin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOxaprozin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinOxaprozin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Oxaprozin is combined with PTC299.Investigational
PuromycinOxaprozin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Oxaprozin can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxaprozin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxaprozin.Approved
QuinineThe metabolism of Oxaprozin can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxaprozin.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxaprozin.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.Experimental, Investigational
ReviparinOxaprozin may increase the anticoagulant activities of Reviparin.Approved
RibostamycinOxaprozin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RifampicinThe metabolism of Oxaprozin can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Oxaprozin can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.Approved, Investigational
RivaroxabanOxaprozin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinOxaprozin may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Oxaprozin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxaprozin.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxaprozin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Oxaprozin.Investigational
SecobarbitalThe metabolism of Oxaprozin can be increased when combined with Secobarbital.Approved, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Seratrodast.Approved, Investigational
SildenafilThe metabolism of Oxaprozin can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinOxaprozin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SorafenibThe metabolism of Oxaprozin can be decreased when combined with Sorafenib.Approved, Investigational
SotalolOxaprozin may decrease the antihypertensive activities of Sotalol.Approved
SP1049COxaprozin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinOxaprozin may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinOxaprozin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxaprozin.Approved
SpironolactoneOxaprozin may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Oxaprozin is combined with SRT501.Investigational
StreptomycinOxaprozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinOxaprozin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Oxaprozin can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Oxaprozin can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineOxaprozin may increase the nephrotoxic activities of Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Oxaprozin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxaprozin.Approved
SulodexideOxaprozin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Oxaprozin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxaprozin.Approved, Withdrawn
TacrolimusOxaprozin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Oxaprozin.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Oxaprozin.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Oxaprozin.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxaprozin.Approved, Investigational
TemafloxacinOxaprozin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxaprozin.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxaprozin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiaprofenic acid.Approved
TicagrelorThe metabolism of Oxaprozin can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Oxaprozin can be decreased when combined with Ticlopidine.Approved
TiludronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiludronate.Approved, Vet Approved
TimololOxaprozin may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tixocortol.Approved
TobramycinOxaprozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Oxaprozin can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxaprozin.Approved
TorasemideOxaprozin may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Oxaprozin.Approved
TranilastThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxaprozin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOxaprozin may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.Approved, Vet Approved
TrimethoprimThe metabolism of Oxaprozin can be decreased when combined with Trimethoprim.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trisalicylate-choline.Approved
TrovafloxacinOxaprozin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxaprozin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Oxaprozin can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinOxaprozin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Oxaprozin can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Oxaprozin.Approved
VoriconazoleThe metabolism of Oxaprozin can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinOxaprozin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOxaprozin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Oxaprozin may increase the anticoagulant activities of Ym150.Investigational
ZafirlukastThe metabolism of Oxaprozin can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Oxaprozin.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zomepirac.Withdrawn
ZorubicinOxaprozin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take with food, usually once a day after breakfast. Food decreases the rate of absorption but not the amount absorbed. Avoid alcohol.
References
Synthesis Reference
  1. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. Pubmed
General References
  1. Heller B, Tarricone R: Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin. 2004 Aug;20(8):1279-90. [PubMed:15324531 ]
External Links
ATC CodesM01AE12
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (47 KB)
MSDSDownload (63.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9512
Caco-2 permeable-0.5255
P-glycoprotein substrateNon-substrate0.7938
P-glycoprotein inhibitor INon-inhibitor0.8801
P-glycoprotein inhibitor IINon-inhibitor0.9047
Renal organic cation transporterNon-inhibitor0.8467
CYP450 2C9 substrateNon-substrate0.7623
CYP450 2D6 substrateNon-substrate0.8163
CYP450 3A4 substrateNon-substrate0.5781
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9327
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.93
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6313
Ames testNon AMES toxic0.9191
CarcinogenicityNon-carcinogens0.9364
BiodegradationReady biodegradable0.6095
Rat acute toxicity1.8484 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9906
hERG inhibition (predictor II)Non-inhibitor0.9123
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories
Packagers
Dosage forms
FormRouteStrength
TabletOral600 mg
TabletOral600 mg/1
Tablet, film coatedOral600 mg/1
Prices
Unit descriptionCostUnit
Daypro 600 mg tablet2.98USD tablet
Daypro 600 mg caplet2.87USD caplet
Oxaprozin 600 mg tablet1.54USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6030643 No1997-05-162017-05-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158-159 °CNot Available
water solubilityInsolubleNot Available
logP4.19HANSCH,C ET AL. (1995)
pKa4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0325 mg/mLALOGPS
logP3.33ALOGPS
logP3.46ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.95ChemAxon
pKa (Strongest Basic)-0.59ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.88 m3·mol-1ChemAxon
Polarizability31.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2,4,5-trisubstituted oxazoles. These are compounds containing an oxazole ring substituted at positions 2, 4 and 5 only. Oxazole is a five-membered aromatic heterocycle with one oxygen, one nitrogen, and three carbon atoms. Isomers include 1,2-oxazole and 1,3-oxazole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassOxazoles
Direct Parent2,4,5-trisubstituted oxazoles
Alternative Parents
Substituents
  • 2,4,5-trisubstituted 1,3-oxazole
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331 ]
  2. Kean WF: Oxaprozin: kinetic and dynamic profile in the treatment of pain. Curr Med Res Opin. 2004 Aug;20(8):1275-7. [PubMed:15324530 ]
  3. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416 ]
  4. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579 ]
  5. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689 ]
  2. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94. [PubMed:9650852 ]
  3. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331 ]
  4. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002 Jul;302(1):18-25. [PubMed:12065695 ]
  5. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416 ]
  6. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23